ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 03, 2021Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. -
Vaccine biotech Icosavax sets terms for $150 million IPO
July 23, 2021Icosavax plans to raise $150 million in its initial public offering by offering 10 million shares at a price range of $14 to $16, as reported by NASDAQ. -
Icosavax raises funding to advance RSV/hMPV vaccine programme
April 08, 2021Icosavax has raised $100m through a Series B financing round to support the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine programme through initial clinical studies.
Pharma Sources Insight January 2025
